Edition:
India

Cipher Pharmaceuticals Inc (CPH.TO)

CPH.TO on Toronto Stock Exchange

1.44CAD
7 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.44
Open
$1.40
Day's High
$1.45
Day's Low
$1.40
Volume
5,040
Avg. Vol
36,251
52-wk High
$1.68
52-wk Low
$0.38

Latest Key Developments (Source: Significant Developments)

Cipher Pharmaceuticals Appoints New Chief Financial Officer
Friday, 3 Jul 2020 

July 2 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS APPOINTS NEW CHIEF FINANCIAL OFFICER.CIPHER PHARMACEUTICALS INC - APPOINTED SCOTT LANGILLE AS ITS NEW CHIEF FINANCIAL OFFICER.CIPHER PHARMACEUTICALS - SCOTT LANGILLE WILL SUCCEED INTERIM CFO NADINE JUTLAH.  Full Article

Cipher Pharmaceuticals Reports Q4 Total Revenue Of $5.9 Mln
Thursday, 26 Mar 2020 

March 25 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.CIPHER PHARMACEUTICALS - QTRLY TOTAL REVENUE DECREASED 8% TO $5.9 MILLION FROM $6.4 MILLION.CIPHER PHARMACEUTICALS - QTRLY EARNINGS PER COMMON SHARE INCREASED TO $0.10.CIPHER PHARMACEUTICALS INC - NOTICE FROM BAUSCH HAS IMPACTED TIMING OF STRATEGIC REVIEW PROCESS.CIPHER PHARMACEUTICALS INC - AT ONSET OF STRATEGIC REVIEW BOARD CONTEMPLATED TWO SCENARIOS FOR CANADIAN COMMERCIAL ASSETS.CIPHER PHARMACEUTICALS - FIRST OPTION UNDER REVIEW OPTION, WAS TO SELL ASSETS TO A SINGLE BUYER OR MULTIPLE BUYERS.CIPHER PHARMACEUTICALS INC - SECOND OPTION WAS TO FIND MOST COST-EFFECTIVE MEANS TO DISTRIBUTE CANADIAN COMMERCIAL PRODUCTS.CIPHER PHARMACEUTICALS INC - PROGRESS HAD BEEN MADE ON BOTH FRONTS PRIOR TO NOTICE FROM BAUSCH.CIPHER PHARMACEUTICALS INC - DUE TO LEGAL DISPUTE WITH BAUSCH, CO MUST NOW FOCUS FIRST OPTION ON SELLING ASSETS INDIVIDUALLY.CIPHER PHARMACEUTICALS INC -EXPECTS DISCUSSIONS WITH GALEPHAR REGARDING NEW PRODUCT OPPORTUNITIES IN 2020.  Full Article

Cipher Pharmaceuticals Inc - QTRLY Total Revenue Increased 20% To $5.8 Million
Thursday, 7 Nov 2019 

Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.CIPHER PHARMACEUTICALS INC - QTRLY TOTAL REVENUE INCREASED 20% TO $5.8 MILLION.CIPHER PHARMACEUTICALS INC - QTRLY NET LOSS OF $0.08 PER BASIC AND DILUTED SHARE.CIPHER PHARMACEUTICALS INC - SUBSEQUENT TO QUARTER END, ON OCT 10, CO RECEIVED A NOTICE OF COMPLIANCE FROM HEALTH CANADA APPROVING SALE OF TRULANCE.  Full Article

Cipher Pharmaceuticals Expects Q2 2019 Earnings Per Share In Range Of $0.04 To $0.05
Monday, 29 Jul 2019 

July 29 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE & PRELIMINARY Q2 FINANCIAL HIGHLIGHTS.CIPHER PHARMACEUTICALS INC - CRAIG MULL HAS BEEN NAMED INTERIM CHIEF EXECUTIVE OFFICER OF CIPHER, REPLACING ROBERT TESSAROLO.CIPHER PHARMACEUTICALS INC - CO HAS COMMENCED A FORMAL SEARCH PROCESS FOR A NEW CHIEF EXECUTIVE OFFICER.CIPHER PHARMACEUTICALS INC - EXPECTS Q2 2019EARNINGS PER SHARE IN RANGE OF $0.04 TO $0.05.CIPHER PHARMACEUTICALS INC - SEES Q2 2019 REVENUE IN RANGE OF $5.4 MILLION TO $5.6 MILLION, COMPARED WITH $6.95 MILLION IN Q2 2018.  Full Article

Cipher Pharmaceuticals Reports Qtrly Income From Continuing Operations At $0.03 Per Share
Friday, 10 May 2019 

May 10 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.CIPHER PHARMACEUTICALS INC - QTRLY TOTAL REVENUE INCREASED 12% TO $5.1 MILLION.CIPHER PHARMACEUTICALS INC - QTRLY INCOME FROM CONTINUING OPERATIONS WAS $0.03 PER SHARE.  Full Article

Cipher Pharmaceuticals Says CFO Stephen Lemieux Has Resigned
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS INC - STEPHEN LEMIEUX, CHIEF FINANCIAL OFFICER AND SECRETARY OF CIPHER HAS RESIGNED TO PURSUE OTHER CAREER OPPORTUNITIES.CIPHER PHARMACEUTICALS INC - HAS COMMENCED A SEARCH FOR A SUCCESSOR CHIEF FINANCIAL OFFICER.CIPHER PHARMACEUTICALS INC - LEMIEUX HAS AGREED TO A CONSULTING AGREEMENT WITH COMPANY TO ASSIST IN ORDERLY TRANSITION OF HIS RESPONSIBILITIES.CIPHER PHARMACEUTICALS INC - NAMED NADINE JUTLAH AS INTERIM CHIEF FINANCIAL OFFICER.  Full Article

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights To Mob-015 From Moberg Pharma
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Cipher Pharmaceuticals Inc ::CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO MOB-015 FROM MOBERG PHARMA FOR THE TOPICAL TREATMENT OF ONYCHOMYCOSIS.CIPHER PHARMACEUTICALS - MOBERG WILL RECEIVE AN UPFRONT PAYMENT OF $0.5 MILLION, ELIGIBLE FOR $14.1 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES.CIPHER PHARMACEUTICALS INC - AGREEMENT ALSO INCLUDES ROYALTIES FROM NET PRODUCT SALES IN CANADA.CIPHER PHARMACEUTICALS - AGREEMENT PROVIDES MOBERG WILL BE RESPONSIBLE FOR MANUFACTURING AND SUPPLYING FINISHED PRODUCT TO CIPHER.  Full Article